Insulet Co. (NASDAQ:PODD) EVP Bradley A. Thomas sold 3,500 shares of the business’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $85.00, for a total transaction of $297,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Bradley A. Thomas also recently made the following trade(s):
- On Wednesday, March 14th, Bradley A. Thomas sold 7,250 shares of Insulet stock. The stock was sold at an average price of $83.81, for a total transaction of $607,622.50.
Insulet Co. (NASDAQ PODD) traded up $0.43 during trading hours on Tuesday, reaching $84.62. The company’s stock had a trading volume of 225,361 shares, compared to its average volume of 513,047. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57. Insulet Co. has a 52 week low of $38.43 and a 52 week high of $85.71. The stock has a market cap of $4,976.67, a PE ratio of -183.96 and a beta of 1.56.
A number of large investors have recently added to or reduced their stakes in the business. Rehmann Capital Advisory Group purchased a new position in Insulet during the 4th quarter valued at about $375,000. Xact Kapitalforvaltning AB purchased a new position in Insulet during the 4th quarter valued at about $381,000. Segall Bryant & Hamill LLC grew its stake in Insulet by 10.5% during the 4th quarter. Segall Bryant & Hamill LLC now owns 200,707 shares of the medical instruments supplier’s stock valued at $13,849,000 after acquiring an additional 19,105 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in Insulet during the 4th quarter valued at about $1,804,000. Finally, Castleark Management LLC purchased a new position in Insulet during the 4th quarter valued at about $16,289,000.
Several equities research analysts have commented on the stock. Jefferies Group reiterated a “buy” rating and issued a $90.00 price target on shares of Insulet in a research report on Friday, February 23rd. Cowen reissued an “outperform” rating and issued a $90.00 price target (up previously from $80.00) on shares of Insulet in a research note on Thursday, February 22nd. Stephens reissued an “equal weight” rating and issued a $81.00 price target (up previously from $60.00) on shares of Insulet in a research note on Thursday, February 22nd. BidaskClub raised Insulet from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Finally, BMO Capital Markets initiated coverage on Insulet in a research note on Monday, March 5th. They issued an “outperform” rating and a $90.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Insulet presently has a consensus rating of “Buy” and a consensus target price of $73.24.
ILLEGAL ACTIVITY WARNING: This report was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2018/03/20/insider-selling-insulet-co-podd-evp-sells-3500-shares-of-stock.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.